{"success":true,"data":{"pressRelease":{"id":"159724","rtpr_id":"nGNX5Trwz4-20261002","ticker":"MLYS","exchange":"NASDAQ","all_tickers":["MLYS"],"title":"Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026","author":"Globe Newswire","published_at":"2026-10-02T20:30:00.111Z","article_body":"RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc.\n(Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to\ntarget hypertension and aldosterone-related adverse outcomes in comorbid\nconditions such as chronic kidney disease, obstructive sleep apnea and other\ndiseases driven by dysregulated aldosterone, today announced that new data\nfrom the Launch-HTN trial of lorundrostat will be presented at the American\nSociety of Nephrology Kidney Week 2026, taking place October 21-25 in Denver,\nColorado.\n\nOral Presentation Details:\n\n Title:    Blood Pressure and Albuminuria Reduction with Lorundrostat in Chronic Kidney Disease Stages 1 to 3 in the Launch-HTN trial                                                                                                                                                                                                   \n Authors:  Liffert Vogt, MD, PhD, Professor of Nephrology and Renal Transplantation at Amsterdam University Medical Center and University of Amsterdam; Patrick J. Heagerty, PhD, Professor of Biostatistics at University of Washington; Sarbani Bhaduri, MD, MS, Vice President of Clinical Research at Mineralys Therapeutics, Inc.  \n\nAbout Launch-HTN \n\nThe Launch-HTN trial (NCT06153693\n(https://www.globenewswire.com/Tracker?data=7eLKjB1bBDLQy_Dt9z_DeBd3BvVpxpS-SQguRHw0D-xjJgCNryWoLLfhidzQ8PJ9m7LplutzzVkkK3Hic1itr4MZ-vyxVLM0KNWma6rE_LEiJQm2stPTwV9BiM2PbySVx9Me38wjS6ZERwWsolE5x-_bn-c9MnqSyiDDVUNUfAEUCeoDpmFzgBSr5xej80gQEDSXicoRAIiU-GpDbD28BRbeaNgVnXHqqxNk0X6UqjDB4afrCsloElhvXPdu5MrWtp7Sc4W8q11VziTnLJGdgV-qAHew73IYYQGclLjJLQg=))\nwas a global, randomized, double-blind, placebo-controlled Phase 3 clinical\ntrial of adults whose blood pressure remained uncontrolled despite being on\ntwo to five antihypertensive medications. Participants were assigned to one of\nthree groups: lorundrostat 50 mg once daily; lorundrostat 50 mg once daily\nwith the option to increase to 100 mg at week six based on prespecified\ncriteria; or placebo. The primary endpoint was change from baseline in\nsystolic blood pressure at six weeks versus placebo, measured by automated\noffice blood pressure monitoring.\n\nAbout Hypertension\n\nHaving sustained, elevated blood pressure (or hypertension) increases the risk\nof heart disease, heart attack and stroke, which are leading causes of death\nin the United States. In 2022, more than 685,000 deaths in the United States\nincluded hypertension as a primary or contributing cause. Hypertension and\nrelated health issues resulted in an estimated annual economic burden of about\n$219 billion in the United States in 2019.\n\nLess than 50% of hypertensive patients achieve their blood pressure goal with\ncurrently available medications. Dysregulated aldosterone levels are a key\nfactor in driving hypertension in approximately 30% of all hypertensive\npatients.\n\nAbout Chronic Kidney Disease (CKD)\n\nCKD, which is characterized by the gradual loss of kidney function, is\nestimated to affect more than 10% of the global population and is one of the\nleading causes of mortality worldwide. According to the U.S. Centers for\nDisease Control and Prevention (CDC), more than 1 in 10 (14%) adults aged 18\nor older (approximately 37 million people) are estimated to have CKD.\nApproximately 21% of adults with high blood pressure are estimated to have\nCKD. The relationship between these conditions is tightly linked: sustained\nhypertension may contribute to impaired kidney function, and progressive\ndecrease in kidney function may lead to worsening blood pressure. When CKD is\npresent in patients with hypertension, the risk of cardiovascular disease and\nmortality rises significantly.\n\nEmerging evidence points to dysregulated aldosterone as a key driver of both\ndiseases. Excess aldosterone promotes sodium retention, vascular inflammation\nand fibrosis, contributing to both uncontrolled blood pressure and kidney\ninjury. Despite the availability of existing therapies, a significant\nproportion of patients remain uncontrolled or undertreated. Early detection\nand targeted interventions that address underlying mechanisms, such as\naldosterone dysregulation, may offer the potential to slow CKD progression,\nreduce cardiovascular risk and improve long-term outcomes. Without effective\nmanagement, CKD can advance to kidney failure, requiring dialysis or\ntransplantation.\n\nAbout Lorundrostat\n\nLorundrostat is an investigational, proprietary, orally administered, highly\nselective aldosterone synthase inhibitor being developed for the treatment of\nuncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as\nrelated comorbidities, such as chronic kidney disease, obstructive sleep apnea\nand other diseases driven by dysregulated aldosterone. Lorundrostat was\ndesigned to reduce aldosterone levels by inhibiting CYP11B2, the enzyme\nresponsible for its production. Lorundrostat has 374-fold selectivity for\naldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro,\nhas an observed half-life of 10-12 hours and demonstrated a 40-70% reduction\nin plasma aldosterone concentration in participants with hypertension.\n\nMineralys has completed six late-stage clinical trials of lorundrostat\nsupporting its efficacy and safety profile while also validating aldosterone\nas an integral therapeutic target in uHTN and rHTN. The clinical program\nincludes two pivotal, registrational trials, the Phase 3 Launch-HTN trial and\nPhase 2 Advance-HTN trial, which support the robust, durable and clinically\nmeaningful reductions in systolic blood pressure by lorundrostat. Lorundrostat\nwas well tolerated in both trials with a favorable safety profile.\n\nAbout Mineralys\n\nMineralys Therapeutics is a biopharmaceutical company focused on developing\nmedicines to target hypertension and related comorbidities such as chronic\nkidney disease, obstructive sleep apnea and other diseases driven by\ndysregulated aldosterone. Its initial product candidate, lorundrostat, is an\ninvestigational, proprietary, orally administered, highly selective\naldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania,\nand was founded by Catalys Pacific. For more information, please\nvisit https://mineralystx.com. Follow Mineralys on LinkedIn\n(https://www.globenewswire.com/Tracker?data=sl16A5JCnYXRtDMu0K2Ofv12xiIECllSykwEEARx4p5rErp6NElmYMP_fD9Hi9wflL5xqF3u1aB8lmOjQjIfXoCn8ASqZtSAl7ITx9Xf30M_XMR5A5wcvhfXlcWS_gBhxoJeGY38aFJeoUsM1kpus_fX3gUT2jgo-fPAUJcwtMA6OJZIIUxjpA2qFVeP2IiJQhL4N3cYA56KRZTqCOouk_LSb9T25lGmqFuK7X8KTdaQsj9a64Ro0VRe1YSZ_C5C4MBHtGjDOYREtSvcs7a_z2rqofRJj8O6_zQE9X2GcDdAEluQ4artVcPC3q9C7n3ez5JIYclrQDDgJR1LNd-OjLcP4-yCHMXUXrVIp6ke9SK-ihFjL_KilwGx-hwXyN9I37KoR3_pCoZE1H6HdyUgPUsa8QaSpdspUWlEPK0ybBxnqAUhD6JsAsqvct5NMQ3565_twD2gdkSZjOsvvprDmLFZkch59POG8Bq33jhLl2R2yRyXMeKAYxe0e0gGkBcZlXpct7WUkdY5FHyw_-Hjpz1ad7__aRPhB5MWsvvK23wXS7VkJ0p606VlSE3ojaMF), X\n(https://www.globenewswire.com/Tracker?data=0BsJ-kjuVATtej92ytsGdjbKZJN9KkPsSt8vlhhju7PVI-RNd11L4a5LwEbcoRHqbdQ296IbMjXyGFy4Z7pCUaaAhkQvcO36Lgzy1vfI70dYrJZ-3ml9jeWVCu_CGLS0fD89f0DMEbrwTr_Cye1KqxRzg8z93hJzvO3fOp0YoZOuejVNb5fQcM1QC72blejovXX6saXszLMgoIjhBKi9hA==) and Bluesky\n(https://www.globenewswire.com/Tracker?data=YeV5CuMrpgVHryw-Ym6n8yuquWB9JIg9Dv7CoxfgT-crgOJDPGLpTBc6wGWCqEY-XqP-hG3xM6TnolSH7egxk_Wony5M19I1XCjfFiCl5z0=).\n\nForward-Looking Statements\n\nMineralys Therapeutics cautions you that statements contained in this press\nrelease regarding matters that are not historical facts are forward-looking\nstatements. The forward-looking statements are based on Mineralys’ current\nbeliefs and expectations and include, but are not limited to, statements\nregarding the potential therapeutic benefits of lorundrostat. Actual results\nmay differ from those set forth in this press release due to the risks and\nuncertainties inherent in Mineralys’ business, including, without\nlimitation: any delays in the Food and Drug Administration’s (FDA) review of\nMineralys’ accepted new drug application (NDA), including as a result of a\ngovernment shutdown or reductions in agency funding or personnel; the results\nof Mineralys’ clinical trials, including the Launch-HTN and Advance-HTN\ntrials, may not be deemed sufficient by the FDA to serve as the basis for\nregulatory approval of lorundrostat; later developments with the FDA may be\ninconsistent with the feedback from prior meetings, including whether the\nproposed pivotal program will support registration of lorundrostat following\nthe FDA’s review of Mineralys’ NDA submission; the risk that future\nfunding under the secured debt facility may not be available on the timeframe\nMineralys expects, or at all, including as a result of its failure to meet the\nconditions required for such funding or failure to comply with the affirmative\nand negative covenants under the debt facility; Mineralys may not be able to\nreach agreement on the proposed termination of its license agreement with\nTanabe on its expected timeframe, or at all; Mineralys’ future performance\nis dependent entirely on the success of lorundrostat; potential delays in the\ncommencement, enrollment and completion of clinical trials and nonclinical\nstudies; Mineralys’ dependence on third parties in connection with\nmanufacturing, research and clinical and nonclinical testing; unexpected\nadverse side effects or inadequate efficacy of lorundrostat that may limit its\ndevelopment, regulatory approval and/or commercialization; unfavorable results\nfrom clinical trials and nonclinical studies; results of prior clinical trials\nand studies of lorundrostat are not necessarily predictive of future results;\nmacroeconomic trends and uncertainty with regard to high interest rates,\nelevated inflation, tariffs and other trade policies, and the potential for a\nlocal and/or global economic recession; Mineralys’ ability to maintain\nundisrupted business operations due to any pandemic or future public health\nconcerns; regulatory developments in the United States and foreign countries;\nMineralys’ reliance on its exclusive license with Tanabe to provide\nMineralys with intellectual property rights to develop and commercialize\nlorundrostat; and other risks described in Mineralys’ filings with the\nSecurities and Exchange Commission (SEC), including under the heading \"Risk\nFactors\" in its annual report on Form 10-K, and any subsequent filings with\nthe SEC. You are cautioned not to place undue reliance on these\nforward-looking statements, which speak only as of the date hereof, and\nMineralys undertakes no obligation to update such statements to reflect events\nthat occur or circumstances that exist after the date hereof. All\nforward-looking statements are qualified in their entirety by this cautionary\nstatement, which is made under the safe harbor provisions of the Private\nSecurities Litigation Reform Act of 1995.\n\nContact:\n\nInvestor Relations\ninvestorrelations@mineralystx.com\n\nMedia Relations\nMelyssa Weible\nElixir Health Public Relations\nEmail: mweible@elixirhealthpr.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2f3e6873-8e64-406e-832e-7df0f6d79a56)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5Trwz4-20261002","title":"Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026","author":"Globe Newswire","ticker":"MLYS","created":"2026-10-02T20:30:00.111Z","tickers":["MLYS"],"exchange":"NASDAQ","article_body":"RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc.\n(Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to\ntarget hypertension and aldosterone-related adverse outcomes in comorbid\nconditions such as chronic kidney disease, obstructive sleep apnea and other\ndiseases driven by dysregulated aldosterone, today announced that new data\nfrom the Launch-HTN trial of lorundrostat will be presented at the American\nSociety of Nephrology Kidney Week 2026, taking place October 21-25 in Denver,\nColorado.\n\nOral Presentation Details:\n\n Title:    Blood Pressure and Albuminuria Reduction with Lorundrostat in Chronic Kidney Disease Stages 1 to 3 in the Launch-HTN trial                                                                                                                                                                                                   \n Authors:  Liffert Vogt, MD, PhD, Professor of Nephrology and Renal Transplantation at Amsterdam University Medical Center and University of Amsterdam; Patrick J. Heagerty, PhD, Professor of Biostatistics at University of Washington; Sarbani Bhaduri, MD, MS, Vice President of Clinical Research at Mineralys Therapeutics, Inc.  \n\nAbout Launch-HTN \n\nThe Launch-HTN trial (NCT06153693\n(https://www.globenewswire.com/Tracker?data=7eLKjB1bBDLQy_Dt9z_DeBd3BvVpxpS-SQguRHw0D-xjJgCNryWoLLfhidzQ8PJ9m7LplutzzVkkK3Hic1itr4MZ-vyxVLM0KNWma6rE_LEiJQm2stPTwV9BiM2PbySVx9Me38wjS6ZERwWsolE5x-_bn-c9MnqSyiDDVUNUfAEUCeoDpmFzgBSr5xej80gQEDSXicoRAIiU-GpDbD28BRbeaNgVnXHqqxNk0X6UqjDB4afrCsloElhvXPdu5MrWtp7Sc4W8q11VziTnLJGdgV-qAHew73IYYQGclLjJLQg=))\nwas a global, randomized, double-blind, placebo-controlled Phase 3 clinical\ntrial of adults whose blood pressure remained uncontrolled despite being on\ntwo to five antihypertensive medications. Participants were assigned to one of\nthree groups: lorundrostat 50 mg once daily; lorundrostat 50 mg once daily\nwith the option to increase to 100 mg at week six based on prespecified\ncriteria; or placebo. The primary endpoint was change from baseline in\nsystolic blood pressure at six weeks versus placebo, measured by automated\noffice blood pressure monitoring.\n\nAbout Hypertension\n\nHaving sustained, elevated blood pressure (or hypertension) increases the risk\nof heart disease, heart attack and stroke, which are leading causes of death\nin the United States. In 2022, more than 685,000 deaths in the United States\nincluded hypertension as a primary or contributing cause. Hypertension and\nrelated health issues resulted in an estimated annual economic burden of about\n$219 billion in the United States in 2019.\n\nLess than 50% of hypertensive patients achieve their blood pressure goal with\ncurrently available medications. Dysregulated aldosterone levels are a key\nfactor in driving hypertension in approximately 30% of all hypertensive\npatients.\n\nAbout Chronic Kidney Disease (CKD)\n\nCKD, which is characterized by the gradual loss of kidney function, is\nestimated to affect more than 10% of the global population and is one of the\nleading causes of mortality worldwide. According to the U.S. Centers for\nDisease Control and Prevention (CDC), more than 1 in 10 (14%) adults aged 18\nor older (approximately 37 million people) are estimated to have CKD.\nApproximately 21% of adults with high blood pressure are estimated to have\nCKD. The relationship between these conditions is tightly linked: sustained\nhypertension may contribute to impaired kidney function, and progressive\ndecrease in kidney function may lead to worsening blood pressure. When CKD is\npresent in patients with hypertension, the risk of cardiovascular disease and\nmortality rises significantly.\n\nEmerging evidence points to dysregulated aldosterone as a key driver of both\ndiseases. Excess aldosterone promotes sodium retention, vascular inflammation\nand fibrosis, contributing to both uncontrolled blood pressure and kidney\ninjury. Despite the availability of existing therapies, a significant\nproportion of patients remain uncontrolled or undertreated. Early detection\nand targeted interventions that address underlying mechanisms, such as\naldosterone dysregulation, may offer the potential to slow CKD progression,\nreduce cardiovascular risk and improve long-term outcomes. Without effective\nmanagement, CKD can advance to kidney failure, requiring dialysis or\ntransplantation.\n\nAbout Lorundrostat\n\nLorundrostat is an investigational, proprietary, orally administered, highly\nselective aldosterone synthase inhibitor being developed for the treatment of\nuncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as\nrelated comorbidities, such as chronic kidney disease, obstructive sleep apnea\nand other diseases driven by dysregulated aldosterone. Lorundrostat was\ndesigned to reduce aldosterone levels by inhibiting CYP11B2, the enzyme\nresponsible for its production. Lorundrostat has 374-fold selectivity for\naldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro,\nhas an observed half-life of 10-12 hours and demonstrated a 40-70% reduction\nin plasma aldosterone concentration in participants with hypertension.\n\nMineralys has completed six late-stage clinical trials of lorundrostat\nsupporting its efficacy and safety profile while also validating aldosterone\nas an integral therapeutic target in uHTN and rHTN. The clinical program\nincludes two pivotal, registrational trials, the Phase 3 Launch-HTN trial and\nPhase 2 Advance-HTN trial, which support the robust, durable and clinically\nmeaningful reductions in systolic blood pressure by lorundrostat. Lorundrostat\nwas well tolerated in both trials with a favorable safety profile.\n\nAbout Mineralys\n\nMineralys Therapeutics is a biopharmaceutical company focused on developing\nmedicines to target hypertension and related comorbidities such as chronic\nkidney disease, obstructive sleep apnea and other diseases driven by\ndysregulated aldosterone. Its initial product candidate, lorundrostat, is an\ninvestigational, proprietary, orally administered, highly selective\naldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania,\nand was founded by Catalys Pacific. For more information, please\nvisit https://mineralystx.com. Follow Mineralys on LinkedIn\n(https://www.globenewswire.com/Tracker?data=sl16A5JCnYXRtDMu0K2Ofv12xiIECllSykwEEARx4p5rErp6NElmYMP_fD9Hi9wflL5xqF3u1aB8lmOjQjIfXoCn8ASqZtSAl7ITx9Xf30M_XMR5A5wcvhfXlcWS_gBhxoJeGY38aFJeoUsM1kpus_fX3gUT2jgo-fPAUJcwtMA6OJZIIUxjpA2qFVeP2IiJQhL4N3cYA56KRZTqCOouk_LSb9T25lGmqFuK7X8KTdaQsj9a64Ro0VRe1YSZ_C5C4MBHtGjDOYREtSvcs7a_z2rqofRJj8O6_zQE9X2GcDdAEluQ4artVcPC3q9C7n3ez5JIYclrQDDgJR1LNd-OjLcP4-yCHMXUXrVIp6ke9SK-ihFjL_KilwGx-hwXyN9I37KoR3_pCoZE1H6HdyUgPUsa8QaSpdspUWlEPK0ybBxnqAUhD6JsAsqvct5NMQ3565_twD2gdkSZjOsvvprDmLFZkch59POG8Bq33jhLl2R2yRyXMeKAYxe0e0gGkBcZlXpct7WUkdY5FHyw_-Hjpz1ad7__aRPhB5MWsvvK23wXS7VkJ0p606VlSE3ojaMF), X\n(https://www.globenewswire.com/Tracker?data=0BsJ-kjuVATtej92ytsGdjbKZJN9KkPsSt8vlhhju7PVI-RNd11L4a5LwEbcoRHqbdQ296IbMjXyGFy4Z7pCUaaAhkQvcO36Lgzy1vfI70dYrJZ-3ml9jeWVCu_CGLS0fD89f0DMEbrwTr_Cye1KqxRzg8z93hJzvO3fOp0YoZOuejVNb5fQcM1QC72blejovXX6saXszLMgoIjhBKi9hA==) and Bluesky\n(https://www.globenewswire.com/Tracker?data=YeV5CuMrpgVHryw-Ym6n8yuquWB9JIg9Dv7CoxfgT-crgOJDPGLpTBc6wGWCqEY-XqP-hG3xM6TnolSH7egxk_Wony5M19I1XCjfFiCl5z0=).\n\nForward-Looking Statements\n\nMineralys Therapeutics cautions you that statements contained in this press\nrelease regarding matters that are not historical facts are forward-looking\nstatements. The forward-looking statements are based on Mineralys’ current\nbeliefs and expectations and include, but are not limited to, statements\nregarding the potential therapeutic benefits of lorundrostat. Actual results\nmay differ from those set forth in this press release due to the risks and\nuncertainties inherent in Mineralys’ business, including, without\nlimitation: any delays in the Food and Drug Administration’s (FDA) review of\nMineralys’ accepted new drug application (NDA), including as a result of a\ngovernment shutdown or reductions in agency funding or personnel; the results\nof Mineralys’ clinical trials, including the Launch-HTN and Advance-HTN\ntrials, may not be deemed sufficient by the FDA to serve as the basis for\nregulatory approval of lorundrostat; later developments with the FDA may be\ninconsistent with the feedback from prior meetings, including whether the\nproposed pivotal program will support registration of lorundrostat following\nthe FDA’s review of Mineralys’ NDA submission; the risk that future\nfunding under the secured debt facility may not be available on the timeframe\nMineralys expects, or at all, including as a result of its failure to meet the\nconditions required for such funding or failure to comply with the affirmative\nand negative covenants under the debt facility; Mineralys may not be able to\nreach agreement on the proposed termination of its license agreement with\nTanabe on its expected timeframe, or at all; Mineralys’ future performance\nis dependent entirely on the success of lorundrostat; potential delays in the\ncommencement, enrollment and completion of clinical trials and nonclinical\nstudies; Mineralys’ dependence on third parties in connection with\nmanufacturing, research and clinical and nonclinical testing; unexpected\nadverse side effects or inadequate efficacy of lorundrostat that may limit its\ndevelopment, regulatory approval and/or commercialization; unfavorable results\nfrom clinical trials and nonclinical studies; results of prior clinical trials\nand studies of lorundrostat are not necessarily predictive of future results;\nmacroeconomic trends and uncertainty with regard to high interest rates,\nelevated inflation, tariffs and other trade policies, and the potential for a\nlocal and/or global economic recession; Mineralys’ ability to maintain\nundisrupted business operations due to any pandemic or future public health\nconcerns; regulatory developments in the United States and foreign countries;\nMineralys’ reliance on its exclusive license with Tanabe to provide\nMineralys with intellectual property rights to develop and commercialize\nlorundrostat; and other risks described in Mineralys’ filings with the\nSecurities and Exchange Commission (SEC), including under the heading \"Risk\nFactors\" in its annual report on Form 10-K, and any subsequent filings with\nthe SEC. You are cautioned not to place undue reliance on these\nforward-looking statements, which speak only as of the date hereof, and\nMineralys undertakes no obligation to update such statements to reflect events\nthat occur or circumstances that exist after the date hereof. All\nforward-looking statements are qualified in their entirety by this cautionary\nstatement, which is made under the safe harbor provisions of the Private\nSecurities Litigation Reform Act of 1995.\n\nContact:\n\nInvestor Relations\ninvestorrelations@mineralystx.com\n\nMedia Relations\nMelyssa Weible\nElixir Health Public Relations\nEmail: mweible@elixirhealthpr.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2f3e6873-8e64-406e-832e-7df0f6d79a56)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-02T20:30:00.159641952Z","server_sent_at_ms":1790973000159},"received_at":"2026-10-02T20:30:00.278Z","source_url":null},"analysis":{"id":"148324","press_release_id":"159724","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Mineralys Therapeutics will present new Launch-HTN Phase 3 data on lorundrostat in an oral session at ASN Kidney Week 2026, held October 21-25 in Denver.\n\nThe presentation covers blood pressure and albuminuria reductions with lorundrostat in chronic kidney disease stages 1 to 3, extending the drug's evidence base into a key comorbidity.\n\nNo new data were disclosed in the release; investors should watch the October 21-25 session for the actual efficacy figures. The company's NDA is under FDA review, with delays cited as a risk factor.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Lorundrostat Phase 3 CKD data heading to ASN Kidney Week -- a teaser ahead of the Oct 21-25 oral presentation."},"keyFigures":{"drugName":"lorundrostat","phaseOfTrial":"Phase 3","customDimensions":{"nct_id":"NCT06153693","half_life":"10-12 hours","trial_name":"Launch-HTN","selectivity":"374-fold aldosterone-synthase vs cortisol-synthase selectivity in vitro","aldosterone_reduction":"40-70% plasma aldosterone concentration reduction"}},"namedEntities":{"people":[{"name":"Liffert Vogt","role":"Professor of Nephrology and Renal Transplantation, Amsterdam University Medical Center; presentation author"},{"name":"Patrick J. Heagerty","role":"Professor of Biostatistics, University of Washington; presentation author"},{"name":"Sarbani Bhaduri","role":"VP of Clinical Research, Mineralys Therapeutics"}],"products":["lorundrostat"],"companies":[{"name":"Mineralys Therapeutics, Inc.","ticker":"MLYS"},{"name":"American Society of Nephrology","relationship":"conference host"},{"name":"Catalys Pacific","relationship":"founder"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Announcement of an upcoming oral presentation of Phase 3 Launch-HTN data (blood pressure and albuminuria reduction in CKD) at ASN Kidney Week; no new efficacy or safety figures disclosed. Modest positive visibility for the lead asset."},"tickerRelevance":{"others":[],"primary":"MLYS"},"globalImportance":18,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap-clinical-stage-biotech","eventGravity":"conference-presentation-announcement","issuerAuthored":true,"newDataDisclosed":false}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Mineralys Therapeutics will present new Launch-HTN Phase 3 data on lorundrostat in an oral session at ASN Kidney Week 2026, held October 21-25 in Denver.\n\nThe presentation covers blood pressure and albuminuria reductions with lorundrostat in chronic kidney disease stages 1 to 3, extending the drug's evidence base into a key comorbidity.\n\nNo new data were disclosed in the release; investors should watch the October 21-25 session for the actual efficacy figures. The company's NDA is under FDA review, with delays cited as a risk factor.","key_figures":{"drugName":"lorundrostat","phaseOfTrial":"Phase 3","customDimensions":{"nct_id":"NCT06153693","half_life":"10-12 hours","trial_name":"Launch-HTN","selectivity":"374-fold aldosterone-synthase vs cortisol-synthase selectivity in vitro","aldosterone_reduction":"40-70% plasma aldosterone concentration reduction"}},"named_entities":{"people":[{"name":"Liffert Vogt","role":"Professor of Nephrology and Renal Transplantation, Amsterdam University Medical Center; presentation author"},{"name":"Patrick J. Heagerty","role":"Professor of Biostatistics, University of Washington; presentation author"},{"name":"Sarbani Bhaduri","role":"VP of Clinical Research, Mineralys Therapeutics"}],"products":["lorundrostat"],"companies":[{"name":"Mineralys Therapeutics, Inc.","ticker":"MLYS"},{"name":"American Society of Nephrology","relationship":"conference host"},{"name":"Catalys Pacific","relationship":"founder"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-02T20:30:05.443Z","global_importance":18,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap-clinical-stage-biotech","eventGravity":"conference-presentation-announcement","issuerAuthored":true,"newDataDisclosed":false}},"durationMs":5122,"modelName":"glm-5.3-flashx"}}